Matching articles for "mResvia"
In Brief: RSV Vaccine (Arexvy) for Ages 50-59
The Medical Letter on Drugs and Therapeutics • July 22, 2024; (Issue 1707)
The recombinant respiratory syncytial virus (RSV)
vaccine Arexvy (GSK) has now received FDA
approval for use in adults 50-59 years old who
are at increased risk for lower respiratory tract
disease (LRTD)...
The recombinant respiratory syncytial virus (RSV)
vaccine Arexvy (GSK) has now received FDA
approval for use in adults 50-59 years old who
are at increased risk for lower respiratory tract
disease (LRTD) caused by RSV. It was previously
approved only for adults ≥60 years old. Two other
RSV vaccines have received FDA approval: Abrysvo,
a recombinant vaccine that is licensed for use in
adults ≥60 years old and in pregnant women at
32-36 weeks' gestation to prevent RSV-associated
LRTD in their infants, and mResvia, an mRNA vaccine
recently licensed for use in adults ≥60 years old that
will be available for the 2024-25 RSV season.